Down-regulation of liver-intestine cadherin enhances noscapine-induced apoptosis in human colon cancer cells

References

• Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:870–873.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Winer E, Gralow J, Diller L, et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol. 2008;27:812–826.
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg. 1999;230:170–178.
   PubMed Web of Science ®Google Scholar
• Esther U. Gastric cancer: predictors of recurrence when lymph-node dissection is inadequate. World J Surg Oncol. 2009;7:69.
   PubMed Web of Science ®Google Scholar
• Ranscht B. Cadherins and catenins: interactions and functions in embryonic development. Cur Opin Cell Biol. 1994;6:740–746.
   PubMed Web of Science ®Google Scholar
• Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol. 1995;7:619–627.
   PubMed Web of Science ®Google Scholar
• Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333–339.
   PubMed Web of Science ®Google Scholar
• Gessner R, Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann NY Acad Sci. 2000;915(1):136–143.
   PubMed Web of Science ®Google Scholar
• Takamura M, Sakamoto M, Ino Y, et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci. 2003;94:425–430.
   PubMed Web of Science ®Google Scholar
• Grötzinger C, Kneifel J, Patschan D, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut. 2001;49:73–81.
   PubMed Web of Science ®Google Scholar
• Dong WG, Yu QF, Xu Y, et al. Li-cadherin is inversely correlated with galectin-3 expression in gastric cancer. Dig Dis Sci. 2008;53:1811–1817.
   PubMed Web of Science ®Google Scholar
• Dong W, Yu Q, Xu Y. Altered expression of a Li-Cadherin in gastric cancer and intestinal metaplasia. Dig Dis Sci. 2007;52:536–542.
   PubMed Web of Science ®Google Scholar
• Berndorff D, Gessner R, Kreft B, et al. Liver-intestine cadherin: molecular cloning and characterization of a novel Ca(2+)-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol. 1994;125:1353–1369.
   PubMed Web of Science ®Google Scholar
• Hinoi T, Lucas PC, Kuick R, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology. 2002;123:1565–1577.
   PubMed Web of Science ®Google Scholar
• Takamura M, Ichida T, Matsuda Y, et al. Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett. 2004;212:253–259.
   PubMed Web of Science ®Google Scholar
• Kwak JM, Min BW, Lee JH, et al. The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum. 2007;50:1873–1880.
   PubMed Web of Science ®Google Scholar
• Boo YJ, Park JM, Kim J, et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Onc. 2007;14:1703–1711.
   PubMed Web of Science ®Google Scholar
• Joshi HC, Zhou J. Noscapine and analogues as potential chemotherapeutic agents. Drug News Perspect. 2000;13:543–546.
   PubMed Web of Science ®Google Scholar
• Ye K, Ke Y, Keshava N, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA. 1998;95:1601–1606.
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Lukyanov YT, Ali MA, et al. Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug. Int J Oncol. 2006;28:1121–1130.
   PubMed Web of Science ®Google Scholar
• Mahmoudian M, Rahimimoghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov. 2009;4:92–97.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Krausz KW, Li F, et al. Metabolic map and bioactivation of the anti-tumour drug noscapine. Br J Pharmacol. 2012;167:1271–1286.
   PubMed Web of Science ®Google Scholar
• Jackson T, Mb C, Ichite N, et al. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol. 2008;63:117–126.
   PubMed Web of Science ®Google Scholar
• Landen JW, Lang R, Mcmahon SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 2002;62:4109–4114.
   PubMed Web of Science ®Google Scholar
• Ke Y, Ye K, Grossniklaus HE, et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother. 2000;49:217–225.
   PubMed Web of Science ®Google Scholar
• Irving AA, Plum LA, Blaser WJ, et al. Cholecalciferol or 25-hydroxycholecalciferol neither prevents nor treats adenomas in a rat model of familial colon cancer. J Nutr. 2015;145:291–298.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang X, Sun W. Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol. 2008;9:375–387.
   PubMed Web of Science ®Google Scholar
• Markman M. Managing taxane toxicities. Support Care Cancer. 2003;11(3):144–147.
   PubMed Web of Science ®Google Scholar
• Zuylen LV, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19:125–141.
   PubMed Web of Science ®Google Scholar
• Boller K, Vestweber D, Kemler R. Cell-adhesion molecule uvomorulin is localized in the intermediate junctions of adult intestinal epithelial cells. J Cell Biol. 1985;100:327–332.
   PubMed Web of Science ®Google Scholar
• Gumbiner B, Simons K. A functional assay for proteins involved in establishing an epithelial occluding barrier: identification of a uvomorulin-like polypeptide. J Cell Biol. 1986;102:457–468.
   PubMed Web of Science ®Google Scholar
• Gumbiner B, Simons K. The role of uvomorulin in the formation of epithelial occluding junctions. Ciba Found Symp. 1987;125:168–186.
   PubMedGoogle Scholar
• Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation. Science. 1984;226:1097–1099.
   PubMed Web of Science ®Google Scholar
• Jourdain A, Martinou JC. Mitochondrial outer-membrane permeabilization and remodelling in apoptosis. Int J Biochem Cell Biol. 2009;41:1884–1889.
   PubMed Web of Science ®Google Scholar
• Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440–442.
   PubMed Web of Science ®Google Scholar
• Megyesi J, Tarcsafalvi A, Seng N, et al. Cdk2 phosphorylation of Bcl-xL after stress converts it to a pro-apoptotic protein mimicking Bax/Bak. Cell Death Discov. 2016;2.
   Google Scholar
• Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell. 2000;103:645–654.
   PubMed Web of Science ®Google Scholar
• Varbiro G, Veres B, Gallyas F, et al. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med. 2001;31:548–558.
   PubMed Web of Science ®Google Scholar